Quick Answer
Cue Biopharma, Inc. reported Diluted EPS of $0.28 per share (loss) for fiscal year 2025.
Cue Biopharma, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.28 | +61.1% |
| 2024 | -$0.72 | +35.1% |
| 2023 | -$1.11 | +25.5% |
| 2022 | -$1.49 | -5.7% |
| 2021 | -$1.41 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.07 | +58.8% | +22.2% |
| June 30, 2025 | -$0.09 | +55.0% | +47.1% |
| March 31, 2025 | -$0.17 | +32.0% | +0.0% |
| September 30, 2024 | -$0.17 | +29.2% | +15.0% |
| June 30, 2024 | -$0.20 | +31.0% | +20.0% |
| March 31, 2024 | -$0.25 | +13.8% | -4.2% |
| September 30, 2023 | -$0.24 | +22.6% | +17.2% |
| June 30, 2023 | -$0.29 | +21.6% | +0.0% |
- Cue Biopharma, Inc. showed an increase of +61.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Cue Biopharma, Inc.’s diluted eps has grown by 80.1% (from $1.41 per share (loss) to $0.28 per share (loss)).
- The most recent figure is from Cue Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: